Speakers Agenda Attendees Overview WSGR website
2015 Conference Agenda


Thursday June 25, 2015
Sharon Heights Golf and Country Club
2900 Sand Hill Road
Menlo Park, CA

6:00 – 9:00 p.m.

Medical Device Dinner Interview with Steve Blank Click here to play audio
Join David Cassak in conversation with Steve Blank on the Lean LaunchPad approach to building Medtech startups. Steve is an entrepreneur with eight tech startups under his belt. He retired to become a writer and educator, and in the process launched the "Lean Startup" movement. Today Steve lectures on entrepreneurship at Berkeley, Stanford, Columbia, NYU and UCSF, and in 2009 was awarded the Stanford University Undergraduate Teaching Award in Management Science.


David Cassak, Managing Partner, The MedTech Strategist


Steve Blank

Friday June 26, 2015

Palace Hotel
2 New Montgomery Street
San Francisco, CA

7:00 – 8:00 a.m.

Conference Registration and Continental Breakfast

8:00 – 8:10 a.m.

Welcome, Casey McGlynn, Partner, Wilson Sonsini Goodrich & Rosati

8:10 – 9:10 a.m.

Venture Capital Today Click here to view video
Getting a new medical device company funded is harder today. An ever-shrinking pool of investors interested in early-stage life science investing, larger capital requirements due to prolonged regulatory and reimbursement timelines, and the need for true sales traction to garner the attention of potential corporate acquirers have all become the hallmarks of the current financing environment. How are investors adapting their financing strategies and business models to accommodate these realities and position themselves for long-term success? Join a panel of Medtech investors to explore their approaches to investing in these changing times.


Casey McGlynn, Partner, Wilson Sonsini Goodrich & Rosati


Steven Hochberg, Partner, Deerfield Management LLC

Alan Kaganov, Partner, US Venture Partners

Dr. Evgeny Zaytsev, Managing Partner, RMI Partners

Eric Milledge, Operating Partner, Endeavour Vision Ltd

9:10 – 9:30 a.m.


9:30 – 10:30 a.m.

Breakout Session 1

Innovative Deal Structures Click here to view video
Several Investors, Corporate Development Executives, and CEOs will review recent corporate partnering transactions. Learn about how young venture backed companies worked with large Medtech consolidators to create win-win structures. Listen to a discussion on key business terms in early and late stage deals. Join a discussion about the differing structures and key terms involved in these transactions.


Scott Murano, Partner, Wilson Sonsini Goodrich & Rosati


Justin Klein, Partner, New Enterprise Associates

Evan Norton, Divisional Vice President, Venture Investments, Abbott Ventures

Mir Imran, Chairman & CEO, InCube Labs

Collaborations Between Japan and Silicon Valley Click here to play audio
There is growing interest from Japan to invest in and collaborate with US Medtech companies, venture funds and incubators, many of which are located in Silicon Valley. For the first time in many years the major Japanese trading companies are focusing on reenergizing their Medtech businesses. This represents a major opportunity for Silicon Valley startups to seek investments from and partnerships with Japanese businesses. Join this panel to learn about the ways in which Japan and Silicon Valley startups are collaborating to finance and develop advanced medical technologies.


Masa Ishii, Managing Director, AZCA, Inc.


Ken McDonnell, General Manager Business Development, Terumo Corporation

Dean Zikira, CEO, Spirometrix

Mike Kleine, President & CEO, Miramar Labs

Fumi Ikeno, Research Associate, Cardiovascular Medicine, Stanford University

A Case Study in Payer/Provider/Medtech Collaboration Click here to play audio
Highmark Blue Cross Blue Shield and its major provider system, the Allegheny Health Network, have created a unique innovation program that is designed to accelerate the adoption of exciting medical devices. The VITAL Innovation program is targeted to FDA approved but unreimbursed devices that are expected to drive quality up at the right cost. The program is attractive to young companies in that they can test their devices, define and measure outcome, clarify the concept of value, explore paths to reimbursement and develop a path to mutual success. This session will share how the program operates from the perspectives of the payor, provider and the companies and explore how this alignment of interests can have relevance for the Medtech industry as a whole. VITAL is a new model that aligns and unites the interests of previously misaligned groups that all seek to improve the health of patients.


Lisa Suennen, Managing Partner, Venture Valkyrie, LLC


David Hall, VP, Enterprise Strategy, Highmark Health

Debra Reisenthel, CEO, Palo Alto Health Sciences

Sara Davis, Senior Director, Healthcare Policy & Reimbursement, TORAX Medical, Inc.

Alan Russell, Executive VP and Chief Innovation Officer , Allegheny Health Network

10:30 – 10:50 a.m.


10:50 – 11:50 a.m.

Breakout Session 2

Corporate Investors and Buyers
Meet corporate investors from two large Medtech consolidators. Learn about the interests of each company in corporate partnering with emerging Medtech companies. Hear about the typical arrangements corporate acquirers like to structure and the therapeutic areas of interest to them today. This panel will also include information on how these arrangements can come undone and ways to make sure the deal ends up as a win-win transaction that will benefit management, investors and the acquirers.


David Cassak, Managing Partner, The MedTech Strategist


Edward Andrle, Vice President, Strategy & Business Development, Sorin Group

Chris Cleary, Vice President of Corporate Development, Medtronic

Successful De Novo 510K Strategies Click here to play audio
Learn the secrets of the De Novo 510k Pathway. Interestingly this alternative to the lengthy premarket approval process has never quite caught on among device makers. In fact, it remains one of the least traveled routes to market for new devices. Meet the executives from emerging Medtech companies as they explain their experience with this pathway and today's slimmed down process to approval. Is the De Novo Pathway right for your device? Ask the experts on this panel.


David Hoffmeister, Partner, Wilson Sonsini Goodrich & Rosati


David Amerson, President & CEO, NeoTract, Inc.

Michael Billig, Co-Founder & Chief Executive Officer, Experien Group

Big Data Meets Medtech Click here to play audio
In this presentation and panel discussion, you will learn how emerging Medtech companies have developed competitive advantage by using Big Data to:

  • Identify unmet market need - and validate the market size for a new product that can address that need
  • Assess the actual market paid amount for a procedure, highlighting the cost-benefits a new technology can deliver to a provider, hospital or payer
  • Identify current treatment patterns that can cause comorbidities and complications - and quantify potential cost savings from a new treatment
  • Empower a Medtech sales force to level the playing field by analyzing the same data payers review and hospitals want to know
  • Minimize new start-up miss-steps or market surprises by testing new technology assumptions on real patient data
  • Undertake longitudinal data analysis, such as Kaplan–Meier estimations, that are so important for manufacturers of implantable devices such as heart valves

Join a panel of experts as they discuss and provide Big Data answers to questions about the efficacy and cost effectiveness of emerging Medtech products.


Tony Likovich, MA, Vice President, Life Sciences, Truven Health Analytics


Dov Gal, DVM, MBA,Vice President RA, CA, QA Clear Flow Inc.

Brian Griffin, MBA, Director Market Analytics, Life Sciences, Truven Health Analytics

11:50 a.m. – 12:10 p.m.


12:10 – 1:10 p.m.

Breakout Session 3

Commercialization Strategies Click here to play audio
Historically building a large sales force to sell important breakthrough Medtech products has been the recipe for a successful acquisition. But has the world changed? What new kind of sales structures will be required in the future? Will sales forces get smaller as the buy decision is increasingly made by the finance department instead of the doctor? Join a panel of CEOs who have launched new products, build sales organizations and created very successful businesses in the past as they look at the evolving commercialization strategies required for product adoption.


Casey McGlynn, Partner, Wilson Sonsini Goodrich & Rosati


David Amerson, President & CEO, NeoTract

Bill Facteau, Chairman, President & CEO, EarLens Corporation

Robert Weigle, CEO, Benvenue Medical, Inc.

Gregory Casciaro, Former President & CEO, Access Closure, Inc.

International Funding Strategies – China Click here to view video
Join a panel of experienced Chinese investors and advisors who can assist you in funding your company or establishing (and funding) a business unit of your company in China. Learn how these transactions are structured and the factors that draw Chinese investors to the US as well as US entrepreneurs to China.


Elton Satusky, Partner, Wilson Sonsini Goodrich & Rosati


Asa Cox, Founding Partner, TPP Healthcare

Chen Yu, Managing Partner, Vivo Capital

Russel Seiber, CEO & Founder, SentreHEART, Inc.

Min Zhou, Ph.D., Founding Partner, China Materialia LLC

Alex Xu, Ph.D., General Manager, German Med Tech (Beijing) Co. Ltd.

Lean LaunchPad Click here to play audio
In today's tough funding climate, innovation in science and technology is not enough. The Lean LaunchPad approach to building Medtech startups focuses on getting founders "out of the building" to solicit direct feedback from customers and critical stakeholders, providing an early testing of core hypotheses and allowing immediate refinements in critical business model assumptions. This "Lean" approach shifts startup thinking from writing business plans and immediate execution to the early testing of critical hypotheses about business, allowing adjustments or pivots on little or no capital. Join Steve Bank and Allan May and several CEOs as they discuss the Lean LaunchPad Concept and the things that entrepreneurs need to have in place before they start to look for money.


Steve Blank


Allan May, Founder & Chairman, Life Science Angels

Dr. Hobart Harris, Englebert Dunphy Endowed Chair in Surgery & Chief of General Surgery, University of California, San Francisco

Kelly Gardner, Ph.D., CEO, Zephyrus Biosciences

1:10 – 2:40 p.m.

Lunch Interview with Eric Fain
Deal making is a critical component of any company's strategy and the need for creative approaches to structuring deals has never been greater.  In this lunch session industry veteran, Eric Fain, Group President, St Jude Medical, talks about how deal making has evolved and about how both big and small companies can think creatively about working together.


David Cassak, Managing Partner, The MedTech Strategist


Eric Fain, M.D., Group President, St Jude Medical

2:40 – 3:40 p.m.

Breakout Session 4

The Changing World of Medtech Investors Click here to play audio
While we focus on the decline in traditional Medtech investors, non-traditional investors have begun investing in Medtech. The list includes software investors interested in controlling hospital costs, biotech investors looking for alternative therapies, international investors tapping US expertise to build Medtech businesses at home; internet investors seeking to change the way devices are sold; and big data investors seeing opportunities to better manage large disease populations. Join this panel as we look at the changing world of Medtech investors.


Uday Kumar, Founder President & CEO, Element Science Inc.


Tom Rodgers, SVP, Managing Director, McKesson Ventures

Andrew Atwell, Principal, Global Innovation Center, Strategic Investments Group

Asha Nayak, Global Medical Director, Intel Corporation

Conrad Wang, Senior Director of Corporate Development, Medtronic

Developing Exit Opportunities Click here to view video
The pace of M&A activity in the Medtech sector has increased during the last 12 months. Medtech consolidators have been busy exercising buyout options they put in place in prior years, while a growing number of Medtech companies have been completing mergers on the eve of regulatory approval or soon after launching their products in the U.S. On the IPO front, a substantial number of companies have filed for and an impressive number have completed IPOs during this last year. For Medtech companies with growing sales, it seems like the window for IPOs continues to be open. With this as a background, our panel will explore recent M&A and IPO transactions with a goal of understanding what a company needs to have in place to successfully complete these transactions.


Philip Oettinger, Partner, Wilson Sonsini Goodrich & Rosati


Rami Elghandour, President, Nevro

Erin McGurk, President, PneumRx

Jeff Hoffman, Senior Managing Director, Guggenheim Securities, LLC

Matthew Ferguson, Chief Business Officer and Chief Financial Officer, Avinger, Inc.


The USPTO Comes to the Silicon Valley Click here to play audio
Obtaining patents is crucial for medical technology companies. Join a panel including the new head of the USPTO Silicon Valley satellite office and a USPTO Supervisory Patent Examiner experienced in medical technologies, as well as experienced patent counsel as they discuss working for and with the PTO. The panel will explore quality improvement initiatives at the PTO, trends, and successful strategies for prosecuting and expediting patent applications in the US, as well as utilizing the resources of the new Silicon Valley satellite PTO office.


James Heslin, Partner, Wilson Sonsini Goodrich & Rosati


Doug Portnow, Associate, Wilson Sonsini Goodrich & Rosati

John Cabeca, Director of the Silicon Valley Office, United States Patent and Trademark Office

Thomas Hughes, Supervisory Patent Examiner, United States Patent and Trademark Office

Lynn Thompson, Vice President of Intellectual Property, Spinal Modulation, Inc.

3:40 – 4:00 p.m.


4:00– 5:00 p.m.

Medtech Innovator 2015 with $300,000 in Prizes Click here to view video
Four early stage companies will be selected out of 300 applications to present their pitch to a panel of judges representing traditional VC, Corporate Venture, Business Development, and Healthcare Provider. These companies will vie for the title of Medtech Innovator. The judges will evaluate the presentations and give feedback to each of the companies that present, and the audience will select the winner using electronic polling. The winner will be profiled in an upcoming issue of the MedTech Strategist and will get a presenting slot at an upcoming Emerging Medical Technologies Summit. They will also go on to compete as one of twenty semi-finalists for $300,000 in prizes at the MedTech Innovator 2015 finals at AdvaMed2015 in San Diego.

New for MedTech Innovator 2015 – Watch the semi-finalists’ 1-minute pitch videos in advance of the WSGR conference and cast your vote online for your picks for the companies that should present at WSGR at: http://medtechinnovator.com/vote/wsgr2015/conference.


Paul Grand, Managing Director, RCT Ventures


Jennifer M. Kozak, Vice President, New Business Development & Strategic Planning, Johnson & Johnson's Global Surgery Group 


Albert A. Lauritano, MS, CLP, Director, Strategic Technology Partnerships,
BD Technologies


Josh Makower, M.D., General Partner, New Enterprise Associates 


Jenell Paul, MSN, RN, Clinical Procurement Specialist and Value Analysis Coordinator, UCLA Health System

5:00 – 6:30 p.m.

Venture Capital Uncorked
Join Wilson Sonsini Goodrich & Rosati for wine tasting after the conference. We will be sampling wines from various wineries, with venture capitalists serving as your sommeliers for the event. This is your chance to try some great wine and learn a little bit more about what each of our local venture firms is looking for in its next deal. It's a great pairing—wine with a venture capital twist.